Anebulo Pharmaceuticals (ANEB) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
7 Jan, 2026Opening remarks and agenda
CEO called the 2025 Annual Stockholders' Virtual Meeting to order at 12:00 P.M. EST on April 4, 2025, and introduced the Board members present.
CFO Dan George was introduced as Secretary of the Meeting, and independent auditors and the Inspector of Elections were acknowledged.
Board and executive committee updates
Board members present included Joseph Lawler (Chairman), Areta Kupchyk, Nathaniel Calloway, and Bimal Shah, with their respective tenures noted.
Shareholder proposals
Six proposals were presented: Board declassification, election of directors, increase in authorized shares, amendment to Stock Incentive Plan, ratification of auditors, and removal of voting restrictions on certain shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Anebulo Pharmaceuticals
- Net loss improved, cash remains strong, and IV selonabant for pediatric use is prioritized amid delisting.ANEB
Q2 202612 Feb 2026 - Registers 15.15M shares for resale after $15M private placement, shifting control to a major holder.ANEB
Registration Filing16 Dec 2025 - Reverse stock split proposed to go private, cashing out small holders at $3.50 per share.ANEB
Proxy Filing2 Dec 2025 - Reverse split and cash-out plan aims to go private, delist, and cut public company costs.ANEB
Proxy Filing2 Dec 2025 - Board seeks approval for declassification, share increases, and key governance changes.ANEB
Proxy Filing2 Dec 2025 - Shareholders will vote on a reverse split to go private, cashing out small holders at $3.50 per share.ANEB
Proxy Filing2 Dec 2025 - Six key proposals—including board declassification and share increases—are up for shareholder vote.ANEB
Proxy Filing2 Dec 2025 - Phase 1 IV selonabant study launched for pediatric cannabis toxicity; Q1 net loss $2.2M.ANEB
Q1 202613 Nov 2025 - IV selonabant for pediatric cannabis toxicity advances, with higher expenses and ongoing strategic review.ANEB
Q4 202529 Sep 2025